1 / 16

TREATMENT

TREATMENT. Mastectomy -traditionally, treatment of breast ca has been surgical -19 century, surgical treatment : local excision ~ total mastectomy : radical mastectomy (remove axillary LN). -20 century : extensions and modifications of the radical

raymond-anderson
Download Presentation

TREATMENT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TREATMENT • Mastectomy -traditionally, treatment of breast ca has been surgical -19 century, surgical treatment : local excision ~ total mastectomy : radical mastectomy (remove axillary LN)

  2. -20 century : extensions and modifications of the radical mastectomy (removal of more local and regional tissue) : lymph node supraclavicular, mediastinal, internal mammary

  3. Modified radical mastectomy -preserves the pectoralis major muscle -no need for skin grafting -no difference in survival rate between radical mastectomy with modified radical mastectomy -better functional and cosmetic result

  4. Total mastectomy -removal of the entire breast, nipple, and areolar complex without the underlying muscles or axillary lymph nodes -low-lying LN in the upper outer portion and low axilla are included -higher risk of the axillary recurrence -regional recurrence will occur in at least 15% to 20%

  5. Adjuvant radiation therapy -the combination of total mastectomy with radiation therapy (Mcwhirther) -earlier trial, adjuvant radiation therapy improves local control but not survival rates

  6. -NSABP(National Surgical Adjuvant Breast Project) :patients were randomly assigned to therapy consisting of total, radical mastectomy , or total mastectomy with radiation therapy :no difference in survival rates :whereas radiation therapy and axillary treatment improved local and regional control

  7. Conservative therapy with or without radiation therapy -radiation therapy or local excision alone : a high local failure rate -radical mastectomy vs. quadrantectomy & axillry LN dessection & radiation (<2 cm, not central, no axillary LN disease(T1N0M0)) :after 15 years, no significant difference in either local control or overall survival rates

  8. -NSABP (satge I or II) :three group- a)modified radical mastectomy b)segmental mastectomy & axillary LN dissection c) b)+post op radiation therapy :lowest local recurrence: c) :no significant in overall survival rate :effective for management of patients with stage I and II

  9. -axillary LN status and the number of involved nodes is the most important prognostic indicator for patients with primary breast cancer -axillary LN dissection :the purposes of staging and the planning of adjuvant chemotherapy

  10. Adjuvant systemic therapy -to eliminate occult metastases during early postop period -reduce the risk of local and distant recurrence -prolong survival in selected breast ca patient -reduce the odds of death by about 25% per year in both node-negative and node-positive patients (negative > positive)

  11. -choosing the patients who should receive adjuvant therapy can be a difficult decision : prognostic and predictive factors identifying patients at risk for recurrence quantifying that risk -recommended for women with a greater than 10% chance of relapse within 10 years

  12. -the patient’s risk of recurrence :nodal involvement, tumor size, nuclear grade estrogen and progesterone receptor status histologic type, proliferative rate, a variety of biologic markers -high risk prognostic factor :benefit from adjuvant cytotoxic or hormonal therapy

  13. -lymph node metastasis : 10 YSR in palpable mass with no systemic Tx -50~60% -the number of LN involved -the presence of extracapsular invasion -tumor size : < 1cm – 27% (10 YSR) > 1 cm – only 9% (10 YSR)

  14. -hormonal receptor status :prognosis & response to hormonal therapy :if positive, improved survival -histological grade -specific tumor biologic marker :HER-2/neu , p53, Ki-67, S-phase fraction

  15. -regimen CMF : cyclophosphamide, methotrexate, 5-fluorouracil -regimen AC : anthracycline, cyclophosphamide : prefered because of short duration (4 cycles for 3 months versus 6 cycles for 6 months) & better tolerance -Taxane (paclitaxel) : benefits were similar in both premenopausal and postmenopausal women

  16. Hormonal therapy -Tamoxifen , an estrogen analogue : pre- or postmenopausal women -20 mg gd daily : reduce -recurrence 50% , death 25% -Tamoxifen + cytotoxic chemoTx : improves survival in women with positive axillary LN and positive estrogen receptor expresson

More Related